Skip to main content
. 2022 Mar 7;12(3):36. doi: 10.1038/s41408-022-00631-7

Fig. 2. Tamoxifen is an ERβ antagonist in DLBCL.

Fig. 2

A Cell viability assay for DLBCL cell lines treated with tamoxifen (TAM) for 48 h in estrogen-containing culture medium. B Cell viability assay for cell lines treated with tamoxifen for 48 h in estrogen-free culture medium. C IC50 values for DLBCL cell lines treated with tamoxifen for 48 h on normal culture medium and ES-free culture medium. D Western blot of U2932 treated with 10 (T10), 15 (T15), and 20 (T20) µM of tamoxifen in RPMI or ES-free RPMI. The effect of Tamoxifen treatment is shown on apoptosis with PARP and DNA damage with γH2AX. E Cell viability assay for cell lines treated with endoxifen for 48 h. F Cell viability assay for cell lines treated with PHTPP for 48 h. G Cell viability assay for cell lines treated with DPN for 48 h. H Competition assay for U2932 treated with tamoxifen and DPN for 48 h. Data were normalized to the control and plotted as the mean ± standard deviation (SD) of n = 3 in all panels. *P ≤ 0.05.